START with a live attenuated vaccine1,2

FluMist Quadrivalent is a live vaccine that is engineered to help prevent influenza, not cause it.1,3-5

Live Attenuated Influenza Vaccine
 
 
 

The virus strains in FluMist Quadrivalent continuously replicate in the lining of the nasopharynx for up to 28 days to induce immunity1,3,4

FluMist Quadrivalent is a live attenuated vaccine,
like the vaccines for MMR, varicella, and rotavirus1
 

Shedding LAIV does not spread illness1,3-5

LAIV strains replicate in the nose, which may lead to shedding1,3-5

The shed viral particles:

  • Are weakened, or attenuated, or do not cause influenza1
  • Would first need to be transmitted and then revert to wild type for the spread of illness to occur1,6-8
  • The odds of reversion to wild-type are 1 in 100 quintillion replication cycles, which would take more than 1,000 years to happen6-8
LAIV=live attenuated influenza vaccine.

No evidence of reversion has been observed in the recovered vaccine strains that have been tested1

FluMist Quadrivalent is engineered to
PROTECT - NOT INFECT
 

LIVE ATTENUATED VACCINE

START with a live attenuated vaccine1,2

FluMist Quadrivalent is engineered to help prevent influenza, not cause it.1,3,5
To learn more, click to open each section below.

Live Attenuated Influenza Vaccine

The virus strains in FluMist Quadrivalent continuously replicate in the lining of the nasopharynx for up to 28 days to induce immunity1,3,4

FluMist Quadrivalent is a live attenuated vaccine, like the
vaccines for MMR, varicella, and rotavirus1,5

REPLICATION = SHEDDING

shedding

REPLICATION = SHEDDING

Viral replication is necessary for the vaccine to work1,3,4

  • Viral shedding occurs as FluMist Quadrivalent (LAIV) strains replicate in the nasopharynx of the recipient after vaccination1,3,4
  • This is to be expected as part of a normal immune response
  • Vaccine virus shedding is measured by obtaining a nasal swab from the anterior nasal mucosa1

SHEDDING LAIV ≠ ILLNESS IN OTHERS

Although shedding occurs in both children and adults to elicit an immune response, it does not result in illness in others1,5

  • The shed virus must first be transmitted, then revert to wild type in order for illness
    in others to occur1,6-8
Shedding LAIV does not equal illness in others
No evidence of reversion has been observed in the recovered vaccine strains that have been tested1,5

Important Safety Information

FluMist Quadrivalent is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist® (Influenza Vaccine Live, Intranasal).

Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FluMist Quadrivalent administration. FluMist Quadrivalent has not been studied in persons with severe asthma or active wheezing.

If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist Quadrivalent should be based on careful consideration of the potential benefits and risks.

FluMist Quadrivalent has not been studied in immunocompromised persons.

The safety of FluMist Quadrivalent in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established.

FluMist Quadrivalent may not protect all individuals receiving the vaccine.

The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FluMist were runny nose or nasal congestion in all persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FluMist Quadrivalent, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FluMist Quadrivalent, 44% reported runny nose or nasal congestion and 19% reported sore throat.

INDICATION

FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is for intranasal administration only.

Please see full Prescribing Information for FluMist Quadrivalent, including Patient Information.